search
Back to results

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Primary Purpose

Type1diabetes

Status
Unknown status
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
Stem cells from human exfoliated teeth
Sponsored by
CAR-T (Shanghai) Biotechnology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type1diabetes

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Understand the purpose of clinical trials, willing to participate and sign informed consent;
  2. Patients with type 2 diabetes are clearly diagnosed according to WHO diagnostic criteria and whose disease duration is more than 5 years, or whose disease duration of type 1 diabetes is more than 1 year;
  3. Islet function test (steamed bread test) : c-peptide fasting 1ng/ml, 2 hours 2ng/ml
  4. Insulin (with or without oral hypoglycemic therapy) and fasting blood glucose (FPG)9.0mmol/L, HbAlc 8.5; The service life of oral hypoglycemic drugs (including metformin, alpha-glucosidase inhibitors or insulin secreting agents) was more than 3 months.
  5. Age 25-70 years old, gender not limited;
  6. Body mass index (BMI) : between 19 and 28kg/m2;
  7. from the date of screening to the end of follow-up, male or female subjects of childbearing age will voluntarily take precautions Pregnancy; Urine pregnancy test was negative when screening women of childbearing age, and serum pregnancy test was performed when necessary to clearly exclude pregnancy.-

Exclusion Criteria:

  1. Patients with gestational diabetes or other special types of diabetes;
  2. Acute complications such as diabetic ketoacidosis and non-ketotic hyperosmolar syndrome were screened within the first month;
  3. Patients who have received other stem cell therapy before screening;
  4. Blood pressure of patients with poor blood pressure control: 160/100mmhg at the time of screening;
  5. Those who took thiazolidinediones, ddp-iv inhibitors and glp-1 drugs within the first 3 months were screened;
  6. Patients who have used insulin for less than 1 year before screening and only injected insulin subcutaneously once a day within the past 3 months;
  7. Patients with pancreatic diseases, including those with acute and chronic pancreatitis and pancreatic tumors;
  8. Patients with other malignant tumors or suspected tumor tendency;Or in the active phase of various infections (including active stage of HBV or HCV infection);Immunodeficiency virus (HIV) positive patients;
  9. Patients with other serious systemic diseases (such as cardiovascular system, respiratory system, digestive system, nervous system, endocrine system, urogenital system, immune system and blood system);
  10. For patients with liver and kidney dysfunction, for example, serum bilirubin TBIL exceeds 1.5 times of the normal upper limit, AST and ALT exceed 2.5 times of the normal upper limit, and serum creatinine Cr exceeds 1.2 times of the normal upper limit;
  11. Is on systemic sex hormone (glucocorticoid), immunosuppressant or cytotoxic therapy;
  12. Disabled patients (blind, deaf, dumb, mentally retarded, physically disabled) as stipulated by law, pregnant women and lactating women;People suffering from mental illness;Patients who take drugs or have a history of adverse drug abuse and alcohol dependence within 5 years;
  13. Patients with contraindications or allergies treated in this study;
  14. Subjects who have participated in other clinical studies in the past 3 months.

Sites / Locations

  • Changhai hospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Stem cells from human exfoliated teeth

Arm Description

Basic treatment: The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia). Stem cell therapy: Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight . Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment. Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed.

Outcomes

Primary Outcome Measures

Total daily insulin dose
change from baseline during treatment
glucose-c peptide release test
relative baseline change during treatment

Secondary Outcome Measures

Islet function
c-peptide and proinsulin
Composite index of glycosylated hemoglobin (HbAlc) and frequency of hypoglycemia
Changes relative to baseline during treatment
Continuous dynamic blood glucose
Changes relative to baseline during treatment

Full Information

First Posted
April 10, 2019
Last Updated
April 18, 2019
Sponsor
CAR-T (Shanghai) Biotechnology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03912480
Brief Title
Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function
Official Title
Study on the Efficacy and Safety of Stem Cells From Human Exfoliated Teeth in Treating Diabetic Patients With Significantly Reduced Islet Function
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 5, 2019 (Actual)
Primary Completion Date
December 30, 2020 (Anticipated)
Study Completion Date
March 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CAR-T (Shanghai) Biotechnology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the safety and efficacy of Stem cells from human exfoliated teeth transplantation in patients with Islet function decreased significantly to provides scientific basis for further clinical studies to verify the safety and efficacy. On the basis of maintaining the original treatment, intravenous drip of dental pulp mesenchymal stem cells.
Detailed Description
Basic treatment: The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia). Stem cell therapy: Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight . Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment. Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Stem cells from human exfoliated teeth
Arm Type
Experimental
Arm Description
Basic treatment: The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia). Stem cell therapy: Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight . Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment. Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed.
Intervention Type
Biological
Intervention Name(s)
Stem cells from human exfoliated teeth
Intervention Description
Intravenous infusion of pulp mesenchymal stem cells
Primary Outcome Measure Information:
Title
Total daily insulin dose
Description
change from baseline during treatment
Time Frame
baseline and 1,2,6 week and 2,3,6,9,12 month
Title
glucose-c peptide release test
Description
relative baseline change during treatment
Time Frame
baseline and 1,2,6 week and 2,3,6,9,12 month
Secondary Outcome Measure Information:
Title
Islet function
Description
c-peptide and proinsulin
Time Frame
1 year
Title
Composite index of glycosylated hemoglobin (HbAlc) and frequency of hypoglycemia
Description
Changes relative to baseline during treatment
Time Frame
1 year
Title
Continuous dynamic blood glucose
Description
Changes relative to baseline during treatment
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Understand the purpose of clinical trials, willing to participate and sign informed consent; Patients with type 2 diabetes are clearly diagnosed according to WHO diagnostic criteria and whose disease duration is more than 5 years, or whose disease duration of type 1 diabetes is more than 1 year; Islet function test (steamed bread test) : c-peptide fasting 1ng/ml, 2 hours 2ng/ml Insulin (with or without oral hypoglycemic therapy) and fasting blood glucose (FPG)9.0mmol/L, HbAlc 8.5; The service life of oral hypoglycemic drugs (including metformin, alpha-glucosidase inhibitors or insulin secreting agents) was more than 3 months. Age 25-70 years old, gender not limited; Body mass index (BMI) : between 19 and 28kg/m2; from the date of screening to the end of follow-up, male or female subjects of childbearing age will voluntarily take precautions Pregnancy; Urine pregnancy test was negative when screening women of childbearing age, and serum pregnancy test was performed when necessary to clearly exclude pregnancy.- Exclusion Criteria: Patients with gestational diabetes or other special types of diabetes; Acute complications such as diabetic ketoacidosis and non-ketotic hyperosmolar syndrome were screened within the first month; Patients who have received other stem cell therapy before screening; Blood pressure of patients with poor blood pressure control: 160/100mmhg at the time of screening; Those who took thiazolidinediones, ddp-iv inhibitors and glp-1 drugs within the first 3 months were screened; Patients who have used insulin for less than 1 year before screening and only injected insulin subcutaneously once a day within the past 3 months; Patients with pancreatic diseases, including those with acute and chronic pancreatitis and pancreatic tumors; Patients with other malignant tumors or suspected tumor tendency;Or in the active phase of various infections (including active stage of HBV or HCV infection);Immunodeficiency virus (HIV) positive patients; Patients with other serious systemic diseases (such as cardiovascular system, respiratory system, digestive system, nervous system, endocrine system, urogenital system, immune system and blood system); For patients with liver and kidney dysfunction, for example, serum bilirubin TBIL exceeds 1.5 times of the normal upper limit, AST and ALT exceed 2.5 times of the normal upper limit, and serum creatinine Cr exceeds 1.2 times of the normal upper limit; Is on systemic sex hormone (glucocorticoid), immunosuppressant or cytotoxic therapy; Disabled patients (blind, deaf, dumb, mentally retarded, physically disabled) as stipulated by law, pregnant women and lactating women;People suffering from mental illness;Patients who take drugs or have a history of adverse drug abuse and alcohol dependence within 5 years; Patients with contraindications or allergies treated in this study; Subjects who have participated in other clinical studies in the past 3 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Qin Huang, Doctor
Phone
13818333125
Email
qxinyi1220@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qin Huang, Doctor
Organizational Affiliation
Changhai houspital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Changhai hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qin Huang, Doctor
Phone
+86 13818333125
Email
qxinyi1220@163.com

12. IPD Sharing Statement

Learn more about this trial

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

We'll reach out to this number within 24 hrs